ROARABLE
FREE $100K
Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / QNRX / forecast
ATOS (33) IMMP (47) AYTU (27) TXMD (34) ⌘ Pro Terminal →

Quoin Pharmaceuticals Ltd. (QNRX) 12-Month Stock Forecast & Price Target Cone

$4.02 -11.45% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $3.93

Quoin Pharmaceuticals Ltd. (QNRX) carries a Roarable Rating of D- (Sell) with 37/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D- • RED ALERT Cap $21.8M
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on QNRX Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is QNRX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 37/100 at a spot price of $4.02 (-11.45% 1D, market cap $21.8M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 5/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 10/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, QNRX ranks #546 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does QNRX compare to ATOS and IMMP in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), QNRX carries a Roarable D- (37/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, ATOS (Atossa Therapeutics Inc.) holds a E grade (33/100 RQD, P/E N/A, ROIC -35.0%, cap $21.7M) and IMMP (Immutep Limited) posts a D grade (47/100 RQD, P/E N/A, ROIC —, cap $22.6M). Among the 5-stock peer group, QNRX leads on earnings multiple (N/A) while TXMD leads on capital efficiency (-12.9% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for QNRX?
▼

Per QNRX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001671502), Quoin Pharmaceuticals Ltd. generated $8.6M in revenue (+29.8% YoY), -$15.8M in net income, and -$13.5M in free cash flow against $20.4M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $3.93 (-2.25%)🧬 Disciplined Float (+0.72% YoY Shares)⚙️ Cash Engine: 7/20 (D-) • 0% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (37/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-8.1% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERRED ALERT • D-
025507510037
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D
Cash (7)Whales (5)SEC (10)Macro (10)CEO (5)
Each axis scored 0–20
12M PRICE TARGET CONE-9.5% Base Target
$25 Bull$4 Base$3 Bear
📬 FREE QNRX RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for QNRX)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (37/100 Composite)
🔍 WHY QNRX SCORES 37/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (27% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 2/9

▲ #2 Bullish Driver: Macro Regime Fit+10/20 pts (27% of score)

FRED Regime × Technicals: 4% of 52W Range • RSI-14 at 50.1 (NEUTRAL RANGE)

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution5/20 pts (-15 pt drag)

Disciplined Float (+0.72% YoY Shares) & executive Form 4 sales trim 15 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
45
Grade D$4.15-2.7% Next Q
Q2 (-2Q)
42
Grade D$4.04+0.2% Next Q
Q3 (-1Q)
40
Grade D$4.05-0.7% Next Q
Current
37
Grade D-$4.02-8.1% Hist 90D α
Trajectory: D (45) → D- (37)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a QNRX Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While QNRX currently carries a cautious 37/100 (D-) rating due to Insider Conviction & Share Dilution (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($5.38) and Max Pain ($4.22) forces dealer call-delta covering toward $24.68.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $QNRX• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “QNRX Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 37%NO 63%Trade / Inspect Odds →
INTERACTIVE 12-MONTH POSITION SIMULATOR

Drag to Test Your QNRX Position Size: $10,000

Shares at $4.02: 2487.6 sh
$1,000$10,000$25,000$50,000$100,000
12M Bear Case FloorTarget $2.84
$7,065
$-2,935 (-29.4%)
12M Consensus BaseTarget $3.64
$9,055
$-945 (-9.5%)
12M Bull Case BreakoutTarget $24.68
$61,393
+$51,393 (+513.9%)

Wall Street Analyst Breakdown & Historical Accuracy Audit (35 Desks)

Street Historical Accuracy: 64/100
● Strong Buy / Buy: 17● Hold: 9● Sell: 9
Wall Street FirmStance12M Target1Y AccuracyTrack Grade
Morgan StanleyInstitutional Equity DeskHOLD$474%A
Goldman SachsSector Coverage LeadUNDERPERFORM$2369%B
JP MorganUS Large-Cap ResearchSELL$358%C
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring QNRX)

  • ✓Walkthrough of QNRX's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
QNRX // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -36.79%🛡️ HOLDING TREND SUPPORT
2026-11-03O $4.15H $4.54L $4.02C $4.02VOL 36.6K
RES: $9.17SUP: $3.87SMA50: $5.38SMA200: $5.99
$10.23$8.34$6.44$4.55$2.66RES $9.17SUP $3.87$4.022026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

QNRX Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 QNRX Butterfly Map → + Track QNRX →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. +29.8% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on QNRX today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for QNRX. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for QNRX today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (QNRX)

Health Care Rank #546 of 1015 ⚔️ ATOS vs QNRX Full Matrix →

1. Head-to-Head Health Care Peer Comparison (QNRX vs. ATOS, IMMP, AYTU, TXMD)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Quoin Pharmaceuticals Ltd. (QNRX) ranks #546 by composite RQD confidence (37/100, grade D-) and #823 by equity capitalization ($21.8M). Within this direct 5-issuer industry benchmark cohort, QNRX leads on earnings valuation at N/A trailing P/E, while TXMD leads on capital efficiency and profitability with -12.9% ROIC and — gross margin. IMMP currently holds the highest overall quantitative score in the immediate peer group at 47/100 (D) compared with QNRX at 37/100 (D-).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
QNRX ACTIVE
Quoin Pharmaceuticals Ltd.
D- 37/100 — — -35.0% -11.45% $21.8M Benchmark Subject
ATOS
Atossa Therapeutics Inc.
E 33/100 — — -35.0% +5.99% $21.7M /atos-vs-qnrx →
IMMP
Immutep Limited
D 47/100 — — — +0.33% $22.6M /immp-vs-qnrx →
AYTU
Aytu BioPharma Inc.
E 27/100 — 69.0% -35.0% +0.52% $21.0M /aytu-vs-qnrx →
TXMD
TherapeuticsMD Inc.
E 34/100 — — -12.9% +0.56% $20.8M /txmd-vs-qnrx →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001671502 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Quoin Pharmaceuticals Ltd. (QNRX) reported GAAP revenue of $8.6M (+29.8% vs. FY2024 revenue of $6.6M , and -78.1% cumulative change since FY2023) , GAAP net income of -$15.8M, operating cash flow of -$13.5M, and free cash flow of -$13.5M (-72.3% YoY). On the balance sheet, QNRX closed FY2025 with $20.4M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $8.6M -$15.8M -$13.5M -$13.5M $20.4M —
FY2024 (FY) 2024-12-31 $6.6M -$9.0M -$7.9M -$7.9M $15.7M —
FY2023 (FY) 2023-12-31 $39.1M -$8.7M -$7.9M -$7.9M — —

3. QNRX Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is QNRX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 37/100 at a spot price of $4.02 (-11.45% 1D, market cap $21.8M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 5/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 10/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, QNRX ranks #546 in composite RQD confidence.

How does QNRX compare to ATOS and IMMP in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), QNRX carries a Roarable D- (37/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, ATOS (Atossa Therapeutics Inc.) holds a E grade (33/100 RQD, P/E N/A, ROIC -35.0%, cap $21.7M) and IMMP (Immutep Limited) posts a D grade (47/100 RQD, P/E N/A, ROIC —, cap $22.6M). Among the 5-stock peer group, QNRX leads on earnings multiple (N/A) while TXMD leads on capital efficiency (-12.9% ROIC).

What are the biggest fundamental strengths and SEC risk factors for QNRX?

Per QNRX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001671502), Quoin Pharmaceuticals Ltd. generated $8.6M in revenue (+29.8% YoY), -$15.8M in net income, and -$13.5M in free cash flow against $20.4M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is QNRX trading relative to its 50-day, 200-day, and 52-week technical levels?

QNRX last traded at $4.02 (-11.45% on volume of 21,379 shares), positioning the stock -25.28% below its 50-day simple moving average ($5.38) and -32.89% below its 200-day simple moving average ($5.99). Across its 52-week range of $3.25 to $23.50, QNRX sits at the 3.8% percentile with a 14-day RSI of 50.1 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($3.52 to $4.52).

Direct Sub-Reports: QNRX RQD Cockpit QNRX 12M Forecast QNRX Earnings & Move QNRX Dividends & DRIP QNRX Insiders & 13F QNRX Whale Options QNRX Profit Sankey QNRX News & Why
ROARABLE RATING BRIEF • RQD 37/100 (D-) ✓ SEC XBRL & RQD VERIFIED

QNRX — Quoin Pharmaceuticals Ltd.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Quoin Pharmaceuticals Ltd. (QNRX) earns a live Roarable RQD composite score of 37/100, corresponding to a D- letter grade (Roarable Sell) at a spot price of $4.02 (-11.45% 1D, market capitalization $21.8M).

  • Fundamental Cash Engine (7/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of —, operating margin of —, and free cash flow yield of —.
  • Whale 13F & Options Flow (5/20) + Insider Conviction (5/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (10/20) + Forensic Balance Sheet (10/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 2/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

Quoin Pharmaceuticals Ltd. (QNRX) is a NASDAQ-listed issuer in the Health Care sector, within the Biotechnology: Pharmaceutical Preparations industry. Per the recent news wire, the company's news flow centers on its QRX003 program, including a peer-reviewed paper on QRX003 for Netherton Syndrome.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Quoin Pharmaceuticals Ltd. (QNRX) reported $8.6M in annual revenue (up from $6.6M in FY2024, +29.8% YoY) and -$15.8M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($39.1M revenue, -$8.7M net income) through FY2025, QNRX scaled operating cash flow to -$13.5M and free cash flow to -$13.5M, backed by $20.4M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (D- • RQD 37/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of — and institutional whale pillar of 5/20. With Fundamental Cash Engine at 7/20 and Institutional Whale Flow at 5/20, sustained execution supports upside toward the upper end of the $3.25 – $23.50 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against — operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Operating in Biotechnology: Pharmaceutical Preparations (Health Care), QNRX carries a macro regime beta of 1.00 and gross margin of —.

  • Key Question #1: Can QNRX sustain or expand its — operating margin and -35.0% ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $8.6M and free cash flow of -$13.5M, how will capital allocation balance growth reinvestment against $0 in total debt?
  • Key Question #3: How sensitive is QNRX's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

QNRX Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Quoin Pharmaceuticals Ltd. (QNRX) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to QNRX Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

QNRX Bull vs. Bear Conversation Board — What's Your Call at $4.02?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON QNRX 🐻 33% BEARISH CONVICTION
1. Pick Your Side on QNRX:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
BR BreakoutHunter RQD DEBATE OPENER • Swing & Catalyst Trader 🐂 BULLISH 🎯 Target: $5.45 (+20.0%)
📌 Pinned Debate

A Canaccord initiation at buy on the company's rare skin disease drug potential is reported in the news wire.

Long QNRX at $4.54 targeting $5.45. A Canaccord initiation at buy on the company's rare skin disease drug potential is reported in the news wire.. Institutional whale score is 5/20 and the risk/reward vs. the $3.25 52-week low is skewed heavily in favor of bulls.

CapAlloc_Nerd 🐂 BULL

@CreditSpread_Watch Fair point on current EV/EBITDA multiples, but you're ignoring the forward operating leverage in Biotechnology: Pharmaceutical Preparations. If gross margin (0.0%) holds, EPS grows into the multiple faster than bears think.

CR CreditSpread_Watch RQD DEBATE OPENER • Balance Sheet Analyst 🐻 BEARISH 🎯 Target: $3.50 (-22.9%)
Spot @ $4.54

Net losses of -$15.8M in FY 2025 against cash of $3.8M, with ROIC at -35% and Piotroski F at 2/9, signal balance-sheet strain.

Fading this rally in QNRX at $4.54. Net losses of -$15.8M in FY 2025 against cash of $3.8M, with ROIC at -35% and Piotroski F at 2/9, signal balance-sheet strain.. With a beta of 1.0 and the stock sitting at $4.54 (52-wk range $3.25–$23.50), the easy multiple expansion is already priced in.

LIVE TAPE SPY $752.10 -1.80% QQQ $681.09 -3.60% DIA $519.34 -1.08% IWM $279.14 -1.68% NVDA $202.06 -1.26% AAPL $338.32 -1.83% MSFT $507.12 -2.83% TSLA $403.82 +1.00% PLTR $178.34 -3.13% SOFI $16.60 -0.95% IBIT $43.35 -5.42% GLD $361.65 -3.59%